BioSig Technologies Inc Financials
This page shows BioSig Technologies Inc (BSGM) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
BioSig’s healthier FY2025 balance sheet is financing-driven, with new cash and asset buildup masking a still cash-consuming operation.
Between FY2024 and FY2025, cash rose from$142K to$20.3M and the current ratio improved from 0.2x to 1.7x, but operating cash flow remained negative at-$10.4M while financing supplied$54.9M ; the liquidity repair came from external capital, not from the business starting to fund itself.
FY2025’s asset surge to
The cost structure also changed shape: R&D fell from
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of BioSig Technologies Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
BioSig Technologies Inc carries a low D/E ratio of 0.41, meaning only $0.41 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 94/100, indicating a strong balance sheet with room for future borrowing.
BioSig Technologies Inc's current ratio of 1.68 is below the typical benchmark, resulting in a score of 29/100. This tight liquidity could limit financial flexibility if cash inflows slow.
BioSig Technologies Inc generates a -347.4% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100.
BioSig Technologies Inc passes 2 of 9 financial strength tests. 1 of 3 profitability signals pass, 1 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, BioSig Technologies Inc generates $0.02 in operating cash flow (-$10.4M OCF vs -$462.8M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
BioSig Technologies Inc earns $-44.4 in operating income for every $1 of interest expense (-$71.1M vs $1.6M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
BioSig Technologies Inc's EBITDA was -$67.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
BioSig Technologies Inc reported -$462.8M in net income in fiscal year 2025.
BioSig Technologies Inc earned $-9.65 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 1186.7% from the prior year.
Cash & Balance Sheet
BioSig Technologies Inc held $20.3M in cash against $0 in long-term debt as of fiscal year 2025.
BioSig Technologies Inc had 50M shares outstanding in fiscal year 2025. This represents an increase of 188.9% from the prior year.
Margins & Returns
BioSig Technologies Inc's ROE was -347.4% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.
Capital Allocation
BioSig Technologies Inc invested $31K in research and development in fiscal year 2025. This represents a decrease of 96.3% from the prior year.
BSGM Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $13K |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $6K | N/A | $6K-68.4% | $19K+216.7% | $6K | N/A | $156K-54.4% | $342K |
| SG&A Expenses | $34.3M | N/A | $4.6M-76.7% | $19.8M+569.3% | $3.0M | N/A | $2.8M-43.8% | $4.9M |
| Operating Income | -$35.7M | N/A | -$6.1M+70.0% | -$20.4M-582.5% | -$3.0M | N/A | -$3.0M+44.3% | -$5.3M |
| Interest Expense | $12.2M | N/A | -$10K-176.9% | $13K | N/A | N/A | N/A | -$5K |
| Income Tax | -$565K | N/A | -$765K | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$46.7M | N/A | -$15.6M+23.5% | -$20.4M-624.5% | -$2.8M | N/A | -$1.9M+51.1% | -$3.9M |
| EPS (Diluted) | $-0.27 | N/A | $-0.47+36.5% | $-0.74-428.6% | $-0.14 | N/A | $-0.12+60.0% | $-0.30 |
BSGM Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $173.3M-7.6% | $187.5M+43.7% | $130.5M+19.0% | $109.7M+2383.5% | $4.4M+424.7% | $842K-40.6% | $1.4M-54.4% | $3.1M |
| Current Assets | $45.9M-36.2% | $71.9M+379.6% | $15.0M+399.6% | $3.0M-24.7% | $4.0M+927.3% | $388K-54.2% | $848K-64.5% | $2.4M |
| Cash & Equivalents | $6.9M-66.2% | $20.3M+83.8% | $11.0M+291.7% | $2.8M-24.3% | $3.7M+2524.6% | $142K-76.9% | $615K-70.8% | $2.1M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | $109K0.0% | $109K+34.6% | $81K+50.0% | $54K |
| Goodwill | $69.8M-1.7% | $71.0M+1.6% | $69.9M+19.1% | $58.7M | N/A | N/A | N/A | N/A |
| Total Liabilities | $14.0M-74.2% | $54.2M-60.5% | $137.3M+21.3% | $113.2M+6642.1% | $1.7M-25.8% | $2.3M+33.1% | $1.7M-43.1% | $3.0M |
| Current Liabilities | $3.3M-92.3% | $42.8M-65.9% | $125.6M+11.0% | $113.2M+6642.1% | $1.7M-25.8% | $2.3M+33.1% | $1.7M-42.8% | $3.0M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $159.0M+19.4% | $133.2M+2013.9% | -$7.0M-92.4% | -$3.6M-238.8% | $2.6M+268.7% | -$1.5M-281.2% | -$405K-6650.0% | -$6K |
| Retained Earnings | -$764.8M-6.5% | -$718.1M-144.2% | -$294.1M-5.6% | -$278.5M-7.9% | -$258.2M-1.1% | -$255.3M-0.4% | -$254.2M-0.8% | -$252.3M |
BSGM Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$10.2M-236.9% | -$3.0M+39.9% | -$5.0M-293.0% | -$1.3M-14.6% | -$1.1M-135.2% | -$474K+68.2% | -$1.5M-0.5% | -$1.5M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | -$1.5M+93.9% | -$24.5M-16776.6% | -$145K | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | -$1.6M-104.5% | $36.8M+174.6% | $13.4M | $0-100.0% | $4.7M+469900.0% | $1K | $0-100.0% | $3.2M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
BSGM Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -40707.7% |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -30115.4% |
| Return on Equity | -29.4% | N/A | N/A | N/A | -107.9% | N/A | N/A | N/A |
| Return on Assets | -26.9% | N/A | -11.9%+6.6pp | -18.6%+45.1pp | -63.6% | N/A | -135.0%-9.0pp | -126.0% |
| Current Ratio | 13.90+12.2 | 1.68+1.6 | 0.12+0.1 | 0.03-2.3 | 2.37+2.2 | 0.17-0.3 | 0.50-0.3 | 0.80 |
| Debt-to-Equity | 0.09-0.3 | 0.41+20.1 | -19.73+11.6 | -31.30-31.9 | 0.64+2.1 | -1.47+2.7 | -4.20+494.3 | -498.50 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is BioSig Technologies Inc profitable?
No, BioSig Technologies Inc (BSGM) reported a net income of -$462.8M in fiscal year 2025.
What is BioSig Technologies Inc's EBITDA?
BioSig Technologies Inc (BSGM) had EBITDA of -$67.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is BioSig Technologies Inc's return on equity (ROE)?
BioSig Technologies Inc (BSGM) has a return on equity of -347.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is BioSig Technologies Inc's operating cash flow?
BioSig Technologies Inc (BSGM) generated -$10.4M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are BioSig Technologies Inc's total assets?
BioSig Technologies Inc (BSGM) had $187.5M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does BioSig Technologies Inc spend on research and development?
BioSig Technologies Inc (BSGM) invested $31K in research and development during fiscal year 2025.
What is BioSig Technologies Inc's current ratio?
BioSig Technologies Inc (BSGM) had a current ratio of 1.68 as of fiscal year 2025, which is generally considered healthy.
What is BioSig Technologies Inc's debt-to-equity ratio?
BioSig Technologies Inc (BSGM) had a debt-to-equity ratio of 0.41 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is BioSig Technologies Inc's return on assets (ROA)?
BioSig Technologies Inc (BSGM) had a return on assets of -246.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is BioSig Technologies Inc's cash runway?
Based on fiscal year 2025 data, BioSig Technologies Inc (BSGM) had $20.3M in cash against an annual operating cash burn of $10.4M. This gives an estimated cash runway of approximately 23 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is BioSig Technologies Inc's Piotroski F-Score?
BioSig Technologies Inc (BSGM) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are BioSig Technologies Inc's earnings high quality?
BioSig Technologies Inc (BSGM) has an earnings quality ratio of 0.02x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can BioSig Technologies Inc cover its interest payments?
BioSig Technologies Inc (BSGM) has an interest coverage ratio of -44.4x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is BioSig Technologies Inc?
BioSig Technologies Inc (BSGM) scores 21 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.